13.10.2015 • News • Dede Willams • Teva • generic

Teva Launches Generic Dutasteride

Israeli generics giant Teva Pharmaceutical Industries has launched a generic equivalent to Glaxo SmithKline’s Avodart (dutasteride) 0.5 mg capsules on the US market.

The active ingredient dutasteride, a 5 alpha-reductase enzyme inhibitor, works by lowering production of the hormone dihydrotestosterone (DHT and is used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

First drugmaker to file for a generic application, Teva said it expects its product to be exclusive for several weeks. GlaxoSmithKline has annual sales of about $467 million from the capsules.

 

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read